TY - JOUR
T1 - Therapeutic novelties in migraine
T2 - new drugs, new hope?
AU - Do, Thien Phu
AU - Guo, Song
AU - Ashina, Messoud
PY - 2019
Y1 - 2019
N2 - BACKGROUND: In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.MAIN BODY: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals.CONCLUSION: Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.
AB - BACKGROUND: In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.MAIN BODY: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals.CONCLUSION: Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.
KW - Analgesics/chemistry
KW - Animals
KW - Calcitonin Gene-Related Peptide Receptor Antagonists/chemistry
KW - Humans
KW - Migraine Disorders/diagnosis
KW - Pyridines/chemistry
KW - Pyrroles/chemistry
KW - Randomized Controlled Trials as Topic/methods
KW - Tryptamines/chemistry
U2 - 10.1186/s10194-019-0974-3
DO - 10.1186/s10194-019-0974-3
M3 - Review
C2 - 30995909
SN - 1129-2377
VL - 20
SP - 37
JO - Journal of Headache and Pain
JF - Journal of Headache and Pain
IS - 1
ER -